Fulcrum Therapeutics(FULC)
$3.75+0.04 (+1.08%)
FULC
Fulcrum Therapeutics financials statements
$3.75
At close:+0.04 (+1.08%)
Want to see FULC full AI Analyst Report?
Fulcrum Therapeutics (FULC) Ratios
519 Followers
Fulcrum Therapeutics Ratios
FULC's free cash flow for Q3 2026 was $-13.38M. For the 2026 fiscal year, FULC's free cash flow was increased by $0.00 and operating cash flow was $-13.38M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 27.40 | 22.63 | 17.71 | 12.41 | 11.77 |
| Quick Ratio | 27.40 | 22.63 | 17.71 | 12.41 | 11.80 |
| Cash Ratio | 15.14 | 5.27 | 1.87 | 2.10 | 1.84 |
| Solvency Ratio | -4.25 | -0.46 | -4.23 | -3.87 | -3.34 |
| Operating Cash Flow Ratio | -4.60 | -0.20 | -6.65 | -5.80 | -4.09 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -37.30 | 0.00 |
| Net Current Asset Value | $ 340.20M | $ 232.24M | $ 219.70M | $ 179.78M | $ 202.54M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.04 | 0.06 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.04 | 0.05 | 0.07 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.04 | 0.06 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.07 | 1.10 | 1.14 | 1.11 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -42.17 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.10 | 0.14 | 0.18 | 0.30 | 0.00 |
| Net Debt to EBITDA | 2.60 | 2.72 | 0.14 | 0.20 | 0.45 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 20.77% | 100.00% | -1110.69% | -263.73% |
| EBIT Margin | 0.00% | -24.79% | -3945.24% | -1768.12% | -422.97% |
| EBITDA Margin | 0.00% | -22.80% | -3867.81% | -1730.05% | -409.85% |
| Operating Profit Margin | 0.00% | -27.37% | -3945.24% | -1774.85% | -422.97% |
| Pretax Profit Margin | 0.00% | -12.16% | -3470.05% | -1732.43% | -421.89% |
| Net Profit Margin | 0.00% | -12.16% | -3470.05% | -1732.43% | -421.89% |
| Continuous Operations Profit Margin | 0.00% | -12.16% | -3470.05% | -1732.43% | -421.89% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.33% | 44.41% | 87.96% | 97.61% | 99.74% |
| Return on Assets (ROA) | -20.44% | -3.73% | -37.77% | -48.47% | -34.40% |
| Return on Equity (ROE) | -21.46% | -4.00% | -41.39% | -55.23% | -38.22% |
| Return on Capital Employed (ROCE) | -24.00% | -8.77% | -45.35% | -53.61% | -37.56% |
| Return on Invested Capital (ROIC) | -23.84% | -8.69% | -44.95% | -52.95% | -37.56% |
| Return on Tangible Assets | -20.44% | -3.73% | -37.77% | -48.47% | -34.40% |
| Earnings Yield | -10.45% | -3.34% | -23.52% | -33.54% | -12.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 23.94 | 1.25 | 5.87 | 4.66 |
| Payables Turnover | 0.87 | 54.46 | 0.00 | 21.11 | 14.56 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | -147.36 |
| Fixed Asset Turnover | 0.00 | 8.35 | 0.23 | 0.40 | 2.60 |
| Asset Turnover | 0.00 | 0.31 | 0.01 | 0.03 | 0.08 |
| Working Capital Turnover Ratio | 0.00 | 0.34 | 0.01 | 0.03 | 0.13 |
| Cash Conversion Cycle | -418.04 | 8.55 | 292.65 | 44.92 | 50.73 |
| Days of Sales Outstanding | 0.00 | 15.25 | 292.65 | 62.21 | 78.28 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | -2.48 |
| Days of Payables Outstanding | 418.04 | 6.70 | 0.00 | 17.29 | 25.07 |
| Operating Cycle | 0.00 | 15.25 | 292.65 | 62.21 | 75.81 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.95 | -0.04 | -1.48 | -2.16 | -2.22 |
| Free Cash Flow Per Share | -0.95 | -0.04 | -1.49 | -2.20 | -2.27 |
| Dividend Paid and CapEx Coverage Ratio | -191.29 | -7.98 | -179.06 | -49.44 | -45.81 |
| Capital Expenditure Coverage Ratio | -191.29 | -7.98 | -179.06 | -49.44 | -45.81 |
| Operating Cash Flow Coverage Ratio | -9.32 | -0.26 | -8.41 | -7.23 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -0.03 | -32.43 | -15.30 | -4.10 |
| Free Cash Flow Yield | -8.43% | -0.86% | -22.10% | -30.23% | -12.82% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.58 | -29.38 | -4.25 | -2.98 | -7.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 3.64 | 147.54 | 51.65 | 32.64 |
| Price-to-Book (P/B) Ratio | 2.05 | 1.20 | 1.76 | 1.65 | 2.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.87 | -116.72 | -4.52 | -3.31 | -7.80 |
| Price-to-Operating Cash Flow Ratio | -11.93 | -131.35 | -4.55 | -3.37 | -7.97 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.33 | 0.13 | -0.51 | 0.44 |
| Enterprise Value Multiple | -7.15 | -13.25 | -3.68 | -2.79 | -7.51 |
| Enterprise Value | 525.46M | 241.74M | 399.10M | 305.86M | 590.12M |
| EV to EBITDA | -7.15 | -13.25 | -3.68 | -2.79 | -7.51 |
| EV to Sales | 0.00 | 3.02 | 142.28 | 48.23 | 30.79 |
| EV to Free Cash Flow | -8.70 | -96.85 | -4.36 | -3.09 | -7.36 |
| EV to Operating Cash Flow | -8.75 | -108.99 | -4.39 | -3.15 | -7.52 |
| Tangible Book Value Per Share | 5.51 | 3.92 | 3.84 | 4.42 | 5.98 |
| Shareholders’ Equity Per Share | 5.51 | 3.92 | 3.84 | 4.42 | 5.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 1.29 | 0.05 | 0.14 | 0.54 |
| Net Income Per Share | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.49 | 0.88 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.79 | 25.60 | 12.11 | 3.64 |
| SG&A to Revenue | 0.00 | 0.46 | 14.85 | 6.57 | 1.59 |
| Stock-Based Compensation to Revenue | 0.00 | 0.18 | 5.28 | 2.11 | 0.58 |
| Income Quality | 0.80 | 0.23 | 0.93 | 0.88 | 0.97 |
Currency in USD

